Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer|HER2-Negative Breast Cancer|Metastatic Epithelial Ovarian Cancer
Interventions: DRUG: Ribociclib|DRUG: PDR001|DRUG: Fulvestrant
Sponsor: Dana-Farber Cancer Institute
Collaborators: Novartis